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Abstract
Ninety percent of HIV-1-infected people worldwide harbour non-subtype B variants of HIV-1. Yet
knowledge of resistance mutations in non-B HIV-1 and their clinical relevance is limited. Although a few
reviews, editorials and perspectives have been published alluding to this lack of data among non-B
subtypes, no systematic review has been performed to date.
With this in mind, we conducted a systematic review (1996–2008) of all published studies performed on
the basis of non-subtype B HIV-1 infections treated with antiretroviral drugs that reported genotype
resistance tests. Using an established search string, 50 studies were deemed relevant for this review.
These studies reported genotyping data from non-B HIV-1 infections that had been treated with either
reverse transcriptase inhibitors or protease inhibitors. While most major resistance mutations in subtype
B were also found in non-B subtypes, a few novel mutations in non-B subtypes were recognized. The main
differences are reflected in the discoveries that: (i) the non-nucleoside reverse transcriptase inhibitor
resistance mutation, V106M, has been seen in subtype C and CRF01_AE, but not in subtype B, (ii) the
protease inhibitor mutations L89I/V have been reported in C, F and G subtypes, but not in B, (iii) a
nelfinavir selected non-D30N containing pathway predominated in CRF01_AE and CRF02_AG, while the
emergence of D30N is favoured in subtypes B and D, (iv) studies on thymidine analog-treated subtype C
infections from South Africa, Botswana and Malawi have reported a higher frequency of the K65R
resistance mutation than that typically seen with subtype B.
Additionally, some substitutions that seem to impact non-B viruses differentially are: reverse transcriptase
mutations G196E, A98G/S, and V75M; and protease mutations M89I/V and I93L.
Polymorphisms that were common in non-B subtypes and that may contribute to resistance tended to
persist or become more frequent after drug exposure. Some, but not all, are recognized as minor
resistance mutations in B subtypes. These observed differences in resistance pathways may impact cross-
resistance and the selection of second-line regimens with protease inhibitors. Attention to newer drug
combinations, as well as baseline genotyping of non-B isolates, in well-designed longitudinal studies with
long duration of follow up are needed.
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Background
The vast majority of cases of HIV infection worldwide are
due to non-subtype B HIV-1 [1]. The HIV-1 group M has
been classified into subtypes, as well as circulating and
unique recombinant forms (CRF and URF respectively),
because of significant natural genetic variation. This diver-
sification includes subtypes A to K and many CRFs and
URFs.
Subtype B is the most prevalent in the western world
(western Europe, the Americas, Japan and Australia),
while non-B subtypes predominate in the rest of the
world: subtype C in sub-Saharan Africa and India;
CRF01_AE in South-East Asia; CRF02_AG in west
Africa,;and subtype A in eastern Europe and northern Asia
[1]. In addition, the proportion of non-B subtypes in
North and South America and western Europe is increas-
ing [2-6]. Thus, it is expected that non-B subtypes will
become more common in the western world over time.
Combination antiretroviral therapy (ART) is now used in
many areas of the world, and HIV resistance to antiretro-
viral drugs (ARVs) has emerged in all locales. Resistance to
ARVs in non-B subtypes is less well studied than in sub-
type B, mainly because of the predominance of subtype B
in those countries in which ARVs first became available.
Yet there is clearly a potential for genetic differences
among subtypes to yield differential patterns of resistance-
conferring mutations in response to ARV pressure. This
possibility is supported by the finding that HIV-1 natu-
rally varies in genetic content among subtypes by as much
as 35% [7].
Because differences in codon sequences at positions asso-
ciated with drug resistance mutations might predispose
viruses of different subtypes to encode different amino
acid substitutions, it is possible that HIV-1 genetic diver-
sity might influence the type of resistance mutations that
emerge upon drug exposure, as well as the rate of emer-
gence of resistance. It is further conceivable that this diver-
sity could affect the degree of cross-resistance to ARVs
within a drug class. The result could impact clinical out-
comes (i.e., virologic suppression and/or preservation of
immunologic function).
As an example, data from studies on the use of single dose
nevirapine (sdNVP) for prevention of mother to child
transmission (PMTCT) have revealed that subtype C is
more prone to acquire nevirapine (NVP) resistance muta-
tions than either subtype A or D, and this can reduce sub-
sequent responsiveness to antiretroviral therapy [8].
Similarly, virological and biochemical data suggest that
amino acid background naturally present in target pro-
teins might affect the magnitude of resistance conferred
by typical antiretroviral resistance mutations [9].
On the other hand, studies on antiretroviral drug resist-
ance in non-B HIV-1 subtypes exposed to chronic suppres-
sive therapy have yielded less definitive results with
respect to the importance of natural HIV-1 genetic diver-
sity in regard to acquisition of drug resistance mutations.
Genotypic ARV resistance data is useful in deciding on
best choice of ARVs for individual treatment and provides
a repository of information on the presence of HIV resist-
ance mutations among non-B subtypes. Because resist-
ance mutations among HIV-1 subtypes may vary, lack of
information on specific resistance mutations in non-B
subtypes may result in non-detection of clinically impor-
tant resistance or misinterpretation of resistance in such
subtypes.
Although HIV resistance databases make efforts to incor-
porate newer genotypic data into their pools of data, the
availability of HIV genotypes from areas of the world with
non-B subtype predominance is remarkably low com-
pared to that of subtype B [10]. The reasons for this scar-
city of data are probably related to reduced availability of
ARV therapy, the high cost of drug resistance testing, and
a paucity of research facilities in resource-limited coun-
tries.
Treatment decisions are often based on CD4 cell quantifi-
cation or clinical signs of therapeutic failure. Viral load
testing is not regularly conducted and resistance testing
may only be performed for participants enrolled in study
cohorts or trials, but not as a matter of general practice.
Hence, a heightened interest in studying HIV resistance in
such countries in the context of programmes for expanded
access to ART does not come as a surprise.
Editorials, perspectives and narrative reviews have been
published on several aspects of non-B HIV subtypes, yet a
systematic review has not been executed. With this in
mind, we conducted a systematic review of all published
and unpublished literature on all aspects of non-B sub-
types, i.e, genetic and biochemical diversity, resistance,
disease progression, transmission and PMTCT.
For this review, the second in the series, we included data
from studies that reported resistance in non-B patients failing
ART. Our primary objective was to synthesize available
knowledge on resistance to ARV in non-B subtype HIV-1
patients taking chronic, suppressive ART. Our secondary
objectives were to: elicit differences in resistance mutations
within non-B HIV-1 subtypes; identify knowledge gaps; and
delineate future research required to fill such gaps.Journal of the International AIDS Society 2009, 12:11 http://www.jiasociety.org/content/12/1/11
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Methods
Identification of studies
Search string, key words and search terms
Our search string included key words and search terms as
follows: Search #1: "HIV"[11] OR "HIV-1"[11] OR "HIV-
1". Search #2: "non-b" [TIAB] OR "subtype*" [TI] OR
"clade" [TI] OR "strain*" [TI] OR "variant*" [TI] OR "non-
subtype B*" [TIAB]. When performing the search in data-
bases that did not accept MeSH terms, we used key words,
such as "subtype", "CRF", "clade", "resistance", "muta-
tions" and "HIV-1 isolates".
Timeframe
Our search strategy covered the period between January
1996 and November 2008. Our search was limited to
publications in English.
Study selection
The study selection methodology is shown in Figure 1. We
searched 11 electronic databases of full-text articles and
conference abstracts, i.e., PUBMED (1996–2008), Web of
Science (1996–2008), EMBASE (1996–2008), BIOSIS
(1996–2008), AIDSLINE (1996–2005), OVID (1996–
2008), Psychinfor (1996–2008), Cochrane controlled tri-
als register (1996–2008), DARE (1996–2008),
COCHRANE (1996–2008), and ILLUMINA (1996–
2007). A total of 5892 references were identified from
these 11 databases. After excluding duplicates (the same
reference found by two database engines), 3691 citations
were considered relevant after the first screen.
We then divided these citations into several groups, i.e.,
genetic and biochemical diversity, disease progression,
PMTCT and transmission studies. On the first screen, we
reviewed the titles of the articles, and if the title was clearly
not related to the topics at hand, the reference was
removed; otherwise it was kept for the second screen (446
citations). In this screen, abstracts were examined and arti-
cles whose content was clearly unrelated to our focus were
removed. If the abstract did not provide enough informa-
Flow diagramme for study selection Figure 1
Flow diagramme for study selection.Journal of the International AIDS Society 2009, 12:11 http://www.jiasociety.org/content/12/1/11
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tion to support an inclusion or exclusion decision, the full
article was reviewed. After this process, only 50 articles
and abstracts were found relevant.
Inclusion criteria
We included full text articles, abstracts and letters, pro-
vided that they contained relevant information and were
of sufficient completeness. Conference abstracts were
searched. These were: Conference on Retroviruses and
Opportunistic Infections (1997–2008), Interscience Con-
ference of Antimicrobial Agents and Chemotherapy
(2000–2008), IAS (2000–2008), Infectious Diseases Soci-
ety of America (2000–2008), and International HIV Drug
Resistance Workshop (2000–2008]). We also searched
bibliographies and references from primary studies and
review articles.
Included studies either: identified mutations selected in
non-B subtype ART recipients; reported non-B subtype
infections identified by clear geographical predominance
or by direct phylogenetic analysis of the genotyped sam-
ples; determined statistical associations of mutations and
therapies; compared relative frequency of resistance muta-
tions shared by B and non-B subtypes; or examined differ-
ences in frequencies among subtypes of polymorphisms
both before and after drug exposure.
Exclusion criteria
Excluded studies either: did not report drug resistance;
reported only biochemical differences between subtypes
in regard to the reverse transcriptase and protease
enzymes; reported the prevalence of resistance mutations
only in ART-naïve patients (n = 115); reported only
genetic diversity; or reported only on transmission of non-
B subtypes.
Data abstraction
The final data abstraction was independently performed
by two reviewers (JLM, NPP). While one reviewer (JLM)
abstracted all the studies, the second reviewer (NPP)
extracted data from a subset (25%). Inter-rate agreement
between reviewers was calculated using kappa statistics
and was high (> 90%). Discordant opinions were resolved
by further review and discussion of the articles until an
agreement was reached.
The data abstraction form included the following general
components: name or names of authors, year of publica-
tion, study location, study design, sample size, HIV-1 sub-
types (details), ART (details), genotyping techniques, and
criteria to define resistance mutations.
We also assessed: the clarity of the research question;
whether therapeutic failure occurred during first-line ther-
apy or later; if there were analyses of mutations according
to use of relevant drugs or drug combinations; the repre-
sentativeness of genotyped isolates; type of sampling; if
there were comparisons among HIV (B or non-B) sub-
types; and if genotypes were compared with consensus
sequences derived from pre-therapy isolates (Table S1;
Additional File 1).
Furthermore, data were also collected on: detection of
novel resistance mutations; measurement of frequency of
resistance mutations before and after ARV exposure; and
details of the relationships of such mutations to a particu-
lar drug or relevant drug combination as well as HIV-1
subtype.
Results
The final 50 study sub-set has been tabulated (Table S2;
Additional File 2) [12-61]. Although a vast majority
(86%) of the studies were observational, a small propor-
tion (4%) were randomized controlled trials.
Primary finding
Overall, similar mutations were present in both B and
non-B subtypes. However, some differences in the types
and frequencies of resistance mutations were reported and
summarized (Table S3; Additional File 3). A synthesis of
study findings with respect to three major ARV drug
classes is listed here:
Findings with respect to NRTI resistance
First, in subtype C-infected patients treated with the NRTI
backbone ZDV/ddI in Botswana, a different thymidine
analogue resistance pathway (67N/70R/215Y) was
observed and reported [43]. Yet this was not reported in
studies from subtype C patients on similar therapy in
India, South Africa or Malawi [16,24,33,41].
Second, the incidence of K65R was geographically differ-
entiated in subtype C. A study from Bostwana reported a
high incidence of K65R (30%) in subtype C patients who
received d4T/ddI + NVP or EFV [26]. Another study from
Malawi detected either K65R or K70E in 23% of patients
failing first-line therapy with d4T/3TC/NVP [33]. A study
from South Africa, meanwhile, detected K65R in 7% and
15% of patients failing first-line or second-line regimens
whose nucleoside backbones included d4T/3TC or ddI/
ZDV [56]. In contrast, other studies from India, Israel,
South Africa and Botswana did not report high frequen-
cies of K65R in subtype C viruses [16,24,29,41,46,50].
K65R also seems to be less frequent in subtype A than in
all other subtypes, despite use of similar treatment regi-
mens [32].
Third, in subtype C isolates from India, the pre-treatment
and post-treatment frequencies of mutations E203D/K/V/
N/A (2% vs 24.7%), H208Y (0% vs 14.7%) and H221Y (0Journal of the International AIDS Society 2009, 12:11 http://www.jiasociety.org/content/12/1/11
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vs 13.7%) suggest a likely role of these mutations in NRTI
resistance [24] and extend previous observations with
subtype B. The degree of statistical association in the study
from India was very strong after exposure to one cycle of
NRTIs, while it was evidently weaker, yet statistically sig-
nificant, in the B subtype study after exposure to one or
two nucleoside reverse transcriptase inhibitors (NRTIs)
[62].
In subtype F from Brazil, a preference for mutations at
position 211 rather than position 210 was seen in NRTI-
resistant isolates [15]. Finally, a higher propensity to
acquire thymidine analog-associated mutations (TAMs)
was reported in patients carrying CRF_06cpx (AGK recom-
binants) compared to patients carrying CRF02_AG from
Burkina Faso [53].
Findings with respect to NNRTI resistance
With regard to non-nucleoside reverse transcriptase inhib-
itor (NNRTI) resistance, the importance of the V106M
mutation in non-B subtypes has been confirmed in recent
years. Six studies confirmed that V106M is frequently seen
in non-B subtypes (C and CRF02_AE) after therapy with
EFV or NVP [24,29,34,43,49,50].
The G190A mutation was also relatively more frequent
among subtype C-infected patients failing NNRTI-based
therapy in Israel and India. In the Israeli, but not the
Indian study, G190A/S was seen as a natural polymor-
phism in subtype C [24,29]. In both studies, the frequen-
cies of these mutations among treated patients were
higher than in subtype B and C drug-naïve patients.
A large survey reported that reverse transcriptase (RT) res-
idues 35 in subtype A, 98 and 106 in subtype C, 35 and 98
in subtype G, as well as 98 in CRF02_AG, were more fre-
quently mutated than was the case in subtype B [38]. In
the same study, other RT positions were less frequently
mutated in other subtypes than in subtype B after expo-
sure to ARVs as follows: RT residues 39 and 179 in subtype
A; residues 35, 48, 121 and 166 in subtype C; residue 39
in subtype D; residue 39 in subtype F; residues 39 and 104
in subtype G; residue 162 and 238 in CRF01_AE; and res-
idue 39 in CRF02_AG [38].
Findings with respect to HIV protease mutations
In the two studies that assessed protease (PR) mutations
in patients failing NFV therapy, the D30N mutation was
never observed in either CRF02_AG or CRF02_AE isolates.
Rather, the 88S mutation emerged after NFV use in
CRF02_AE and after IDV use in subtype B [17,21]. A third
study also reported an absence of the D30N mutation in
CRF02_AE patients receiving protease inhibitors (PIs),
including NFV, but no information on the specific PI used
by the patients was available [51].
A low frequency of D30N was seen in subtype C isolates
from Israel after NFV usage versus a higher frequency in
subtype C viruses from Botswana [25,30], suggesting that
subtype C viruses from Ethiopia (the origin of the Israeli
samples) and southern Africa might behave differently.
The M89I/V mutations have been identified in F, G and C
but not other subtypes [59]. The V82M mutation was
found to emerge in subtype G, but not in B [13]. Finally,
the L90M mutation is rare in subtype F, but common in
subtype B from Brazil [18].
Kantor et al reported that positions more frequently
mutated in PR in non-B subtypes included residues 14 in
subtype A, 13 and 64 in subtype C, 37 and 65 in subtype
F, 71 in subtype G, 62 and 64 in CRF01_AE, and 15 and
71 in CRF02_AG [40].
Additionally, positions that were less frequently mutated
in non-B subtypes after exposure to ARVs include changes
at PR residues 10, 20 and 63 in subtype A, residues 20, 53,
63, 74 and 82 in subtype C, residues 13 and 20 in subtype
D, residues 10, 14, 20 and 77 in subtype F, residues 20, 67,
73, 82 and 88 in subtype G, residues 20, 63, 82 and 89 in
CRF01_AE, and residue 20 in CRF02_AG [41]. Another
study identified a possible role of mutations at positions
13, 16, 33, 37, 41, 57, 65, 72, 74 and 89 in resistance to
PIs [58].
Rate of acquisition of resistance mutations
Only one study compared the rate of accumulation of
resistance mutations between patients infected with sub-
types B versus C, and revealed higher rates of emergence
of NRTI and PI resistance mutations and equal rates of
emergence of NNRTI mutations in subtype B compared to
C [48]. Although retrospective, this study measured fac-
tors that could influence the acquisition of resistance;
these included CD4 cell count, viral load at initiation of
ART, and time of resistance genotyping.
Discussion
The overall findings in our review are consistent with the
notion that mutations associated with resistance in B
resemble those in non-B subtypes, and might therefore
lead to the conclusion that HIV-1 genetic diversity bears
only a slight effect on ARV-selected mutations. However,
this idea is mistaken, and, there are genuine subtype dif-
ferences in both the types of resistance mutations and pre-
ferred pathways of resistance.
Indeed, certain mutations may emerge almost exclusively
in some non-B subtypes. This review makes it evident that
the studies performed on this topic have been diverse and
most were not specifically designed to assess the impact of
HIV genetic diversity on resistance to ARVs in the contextJournal of the International AIDS Society 2009, 12:11 http://www.jiasociety.org/content/12/1/11
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of chronic antiretroviral therapy. Some of the reasons for
these limitations and recommendations for future studies
and/or secondary analyses of available data are discussed
below.
Types and frequency of resistance mutations
Among the most important differences are: the protease
mutation 82 M in subtype G versus 82A/F/S/T in the oth-
ers; 88D in subtype B versus 88S in C and AG; and the RT
mutation V106M in subtype C and CRF01_AE versus
V106A in subtype B. Also, polymorphisms at RT residue
98, common in subtype G, are associated with NNRTI
resistance in subtype B, and may lower the resistance bar-
rier and duration of efficacy of NNRTIs [14].
The available evidence indicates that the frequency of
some resistance mutations shared by B and non-B sub-
types can vary after failure of first-line therapeutic regi-
mens, as in the case of the K65R mutation. These
differences in type and frequency of resistance mutations
should not be underestimated vis-à-vis impact on remain-
ing active regimens in resource-limited settings.
The 67N/70R/215Y TAM pathway reported to predomi-
nate in subtype C in Botswana will probably be ade-
quately detected by most resistance algorithms since it
does not involve new mutations. It seems, though, that
such a pathway is uniquely associated with d4T/ddI expo-
sure in subtype C since no other study in our review
reported this pattern. Notably, subtype C studies from
South Africa, Malawi and India, in which d4T or ZDV plus
3TC as backbone have been employed, and a study on
CRF01_AE exposed to ZDV/ddI failed to report this pat-
tern [16,24,33,39].
The finding of higher frequencies of the K65R mutation in
subtype C and not other subtypes [26,33,56] suggests that
subtype C viruses may enjoy a particular predisposition
toward acquiring this mutation, and this has been
described in vitro. A subtype C RNA template mechanism
has been proposed to explain this phenomenon in which
neither codon bias nor RT enzyme subtype plays a role
[63,64].
However, not all studies have found a higher prevalence
of K65R in subtype C, and it is possible that such discord-
ance is related to the duration of sub-optimal therapy in
patients inadvertently experiencing virological failure. All
studies reporting a low frequency of K65R have moni-
tored virologic failure, while those that found high fre-
quencies of this mutation monitored therapeutic failure
based on immunological or clinical parameters, which
require several months of surveillance after virological
failure and resistance are suspected [65-67].
Bias may also have been introduced by virtue of the fact
that many patients began therapy with ZDV, which selects
for TAMs that can in turn mitigate against the selection of
K65R. The foregoing heightens the need to detect virolog-
ical failure as early as possible in ART-access programmes
worldwide.
Rate of emergence of resistance
Only one study that compared rates of emergence of
resistance between subtypes in patients receiving suppres-
sive ART actually reported a lower risk of accumulation of
major resistance mutations in subtype C than in B [48].
This is paradoxical, since all the ARV drugs employed were
originally designed to target subtype B.
Qualitatively, the major mutations that emerged in both
subtypes were the same. Viral, host and drug factors were
mostly the same among participants. The authors inferred
that both subtype B and C patients possessed similar pro-
files of virologic failure after use of the same ART regi-
mens. Therefore other unknown factors might have been
responsible for any subtype differences observed.
However, subtype C HIV-1 might not need to accumulate
a similar number of B-defined major mutations to reach
an equivalent level of resistance. For example, several
minor resistance mutations in subtype B PR occur more
frequently as natural polymorphisms in subtype C, e.g.,
36I, 89M, 93L.
Thus, it is conceivable that there might be a lower accu-
mulation threshold of major mutations in C subtypes if
we assume that these natural polymorphisms act similarly
in subtype C as they do when present as secondary resist-
ance mutations in subtype B. This hypothesis requires fur-
ther testing.
Limitations of available evidence
Important heterogeneity across studies was found in
terms of design, reporting, location, mutations, and com-
parisons. Study designs were cross-sectional, longitudinal
and clinical.
Some studies were unique in design and limited in infor-
mation, thus restricting the possibilities for comparison.
For instance, one study evaluated codon usage in subtypes
B, C and F [25]; another study surveyed the frequency of
the 82 M mutation, without making reference to other
mutations [19].
Also, studies were inconsistent in reporting follow up,
adequate sample size, representativeness of the sample,
comparisons, study designs and isolate sequences. They
also lacked details on the level of ARV experience ofJournal of the International AIDS Society 2009, 12:11 http://www.jiasociety.org/content/12/1/11
Page 7 of 11
(page number not for citation purposes)
patients, as well as clarity of objectives. Reporting of con-
sistent measures was lacking for frequency of mutations
by subtype and by specific drugs or drug combinations.
Several studies reported pooled non-B data, pooling infor-
mation from several subtypes as one category. Studies
have also addressed different research questions and used
non-equivalent NRTI backbones, e.g., ZVD/ddI and ZDV/
3TC. Several studies grouped mutations by drug class
without information on the nature of the regimen at viro-
logic failure, and have reported resistance in different
ways, e.g., different algorithms or resistance lists.
Furthermore, no study in non-B subtypes reported geno-
typing data prior to ARV exposure. Only one paper
reported having generated a baseline consensus sequence
from HIV sequences obtained in the geographical region
in which the study was conducted, but was limited in that
the population used to generate the consensus sequence
was different from the ART-exposed population [24].
Hence, only a narrative description was possible.
Not all studies could relate mutations to specific drugs. A
majority of studies were conducted in patients failing sec-
ond-line or third-line ART, while a small minority (five)
were conducted in patients who failed first-line ART regi-
mens [14,21,24,37,41].
In addition, few longitudinal studies evaluated resistance
mutations in a particular non-B subtype and compared
genotypes of viruses from treated patients on the basis of
consensus sequences, i.e., of the same subtype. The result
is that available knowledge on PI resistance mutations
seems to originate from one or two studies that represent
a very small sample of the worldwide patient population.
In addition, 22 of 50 (44%) of studies performed in indi-
viduals with non-B infections evaluated drugs or regimens
no longer recommended by international guidelines, e.g.,
the NRTI backbones, d4T/ddI or ZDV/ddI, and the PIs,
IDV and NFV [68-70].
Our review also included more recent studies from several
African countries and India that evaluated first-line thera-
peutic regimens that employed ZDV/3TC or d4T/3TC,
plus either NVP or EFV. These studies have not reported
any novel mutations, but they did detect important asso-
ciations of polymorphisms with ARV resistance. Desh-
pande et al discovered that the A98G/S substitution was
strongly associated with NNRTI treatment failure in sub-
type C [24].
Prior to that publication, the A98G/S substitution was not
considered to be important in all ARV resistance algo-
rithms, apparently because subtype C wild type viruses
independently contain A98G/S as a common polymor-
phism [29]. Desphande et al also observed a number of
RT polymorphisms that increased in frequency after ther-
apy at positions K20, E28, W88, V90, and V108 [21]. The
A98S polymorphism is also frequently found in subtype
G and might consequently contribute to resistance in that
subtype.
ARV cross-resistance in non-B subtypes
Resistance in non-B subtypes has rarely been reported on
the basis of single drugs or NRTI backbones that are cur-
rently in use in Western countries. Rather, mutations have
been reported for drug classes. Hence, cross-resistance can
be estimated only for some NRTIs and NNRTIs, but not
for most PIs that are the only drugs being used as part of
second-line regimens in most regions of the world.
Hence, well-informed guidance for sequential use of PIs
in populations affected by non-B subtypes is difficult to
obtain. For instance, in the case of NFV, the potential for
cross-resistance in viruses of CRF01_AE and CRF02_AG
origin could be higher than has been observed in subtype
B due to the preferential selection of the N88S and L90M
mutations. Of note, NFV was the most commonly used PI
in resource-limited settings until recently.
Similarly, NRTI backbones may also vary in the muta-
tional profile that they select, based on drug combina-
tions. Newer drugs, e.g., TDF and ATV/r are now preferred
in resource-rich countries and need to be studied in non-
B subtypes to determine whether they can lower risks of
accumulation of resistance mutations. This is important
in view of the higher propensity of subtype C to acquire
K65R.
HIV resistance databases continue to enter HIV genotype
data from non-B subtype variants. So far, however, very
few datasets, such as the Stanford HIV resistance database
and that of the ANRS, provide information for drugs that
have become first-line therapy in developed countries,
including tenofovir, atazanavir, and fosamprenavir, as
well as newer drugs such as tipranavir, darunavir, maravi-
roc, etravirine and raltegravir.
Implications for future research
The clinical and prognostic implications of the preferen-
tial emergence of some mutations in non-B viruses, as
well as changes in the frequencies of these mutations, are
largely unstudied and unknown. Future research on the
role of polymorphisms in non-B subtypes, that increase in
frequency after drug exposure and that may contribute to
drug resistance, e.g., A98G/S in RT and M36I and K20I in
PR, is required.Journal of the International AIDS Society 2009, 12:11 http://www.jiasociety.org/content/12/1/11
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This may be particularly important in parts of Africa, in
which treatment failure may exceed 40% of patients after
two years [71], and in India, where resistance rates of 80%
to two drug classes have been reported after failure on
first-line regimens that employed NRTI/NNRTI combina-
tions [46].
No study has yet tested the degree of resistance or cross-
resistance that certain mutational combinations (67N/
70R/215Y) may confer in vitro. It is similarly important
that future studies assess pre-treatment and post-treat-
ment genotypes in order to detect associations of certain
polymorphisms with drug resistance, including variations
of polymorphisms in viruses of the same subtype that are
located in different geographical areas. This might
improve the appropriateness of selection of certain drugs
over others in the context of second-line or third-line ther-
apeutic options.
In order to better recognize inter-subtype differences,
more longitudinal studies on the response to first-line
ART combinations, or first-time exposure to a new drug,
are needed. In these studies, it would be advisable that
pre-therapy and post-therapy genotype resistance testing
be performed, and that equivalent and newer drug combi-
nations be examined.
Because clinical trials are difficult to execute in resource-
limited settings, analysis of longitudinal data of this type
might be the only way to estimate the possible potential
advantages of one combination over others. Current data
cannot ascertain whether or not HIV subtype is a factor
protecting against or predisposing to therapeutic failure,
and what therapeutic options are best and/or acceptable
in subsequent salvage settings.
The generation of ARV resistance data for subtype B has
been possible because most clinical trials have been per-
formed in populations carrying such viruses. By contrast,
only two clinical trials identified in this review provided
sequencing data of non-subtype B viruses, and the NRTI
combinations used in these studies are now considered to
be sub-standard [68,72,73].
As a result, only NFV has been well studied in non-B sub-
types [74-76], while very few data have been published on
other PIs in this context. Therefore, discrepancies among
HIV resistance interpretative algorithms for resistance test-
ing may not be quickly resolved.
Limitations and strengths of this review
We limited our review to RT and PR inhibitors and did not
examine other drug classes currently in clinical use. Our
review is subject to reporting and publication bias. We
evaluated publications in the English language only.
However, we tried to minimize publication bias by per-
forming a broad search that included multiple databases,
conferences and abstracts. We were unable to retrieve lit-
erature from developing countries and resource-limited
settings reported in languages other than English. This
may affect the epidemiological strength of our conclu-
sions. Owing to the presence of significant heterogeneity
in reporting of outcomes, we could not pool data.
Nevertheless, our review has several redeeming factors in
that it followed a written protocol, conducted a thorough
search to identify relevant studies, and contacted authors
to obtain articles not found through conventional library
resources. We also attempted to reduce publication bias
by including published studies, abstracts, letters, and brief
reports.
Conclusion
Our results suggest that the majority of ARV resistance
mutations will be shared by viruses of all subtypes. Muta-
tions conferring resistance to NRTIs and NNRTIs are the
most similar among different subtypes. However, no clin-
ical study has yet reported mutational patterns for PIs
among non-subtype B viruses or compared newer PIs, e.g.,
atazanavir, lopinavir, amprenavir and darunavir, with
older drugs.
Therefore, our understanding of the impact of HIV-1
genetic diversity on ARV drug resistance is incomplete and
the effect on clinical outcomes will be difficult to measure
in the context of chronic suppressive ART.
There is a need to more fully understand the role of HIV-
1 natural and post-ARV exposure genetic variation so as to
inform on the optimal use of limited ARV options in most
of the world. Better recording of clinical factors and longer
follow up of patients will be required to determine
whether novel mutations might confer cross-resistance
more efficiently in certain subtypes than others.
Future studies need to be performed longitudinally to
include pre-therapy genotyping, and to report results not
only on the basis of drug class, but also in a context of the
NRTI backbones that were used. It will also be important
to know whether certain drugs or drug classes were being
employed for the first time in the patients being treated.
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